证券代码：002940 证券简称：昂利康 公告编号：2026-007 关于获得药品注册证书的公告 二、药品的其他相关信息 碳酸司维拉姆片用于控制正在接受透析治疗的慢性肾脏病（CKD）成人患 者的高磷血症；用于控制血清磷≥1.78mmol/L 但并未进行透析的慢性肾脏病成 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 近日，浙江昂利康制药股份有限公司（以下简称"公司"）收到国家药品监 督管理局（以下简称"国家药监局"）签发的碳酸司维拉姆片《药品注册证书》， 现将有关情况公告如下： | 药品通用名称 | 碳酸司维拉姆片 | | --- | --- | | 主要成份 | 碳酸司维拉姆 | | 剂型 | 片剂 | | 申请事项 | 药品注册（境内生产） | | 注册分类 | 化学药品 类 4 | | 规格 | 0.8g | | 受理号 | CYHS2401665 | | 药品批准文号 | 国药准字 H20263512 | | 药品批准文号有效期 | 至 2031 年 03 月 02 日 | | 上市许可持有人 | 名称：浙江昂利康制药股份有限公司 | | | 地址： ...

证券代码：002940 证券简称：昂利康 公告编号：2026-006 浙江昂利康制药股份有限公司 关于获得药品注册证书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 近日，浙江昂利康制药股份有限公司（以下简称"公司"）收到国家药品监 督管理局（以下简称"国家药监局"）签发的腺苷钴胺胶囊《药品注册证书》， 现将有关情况公告如下： | 药品通用名称 | 腺苷钴胺胶囊 | | --- | --- | | 主要成份 | 腺苷钴胺 | | 剂型 | 胶囊剂 | | 申请事项 | 药品注册（境内生产） | | 注册分类 | 化学药品 类 3 | | 规格 | 0.5mg | | 受理号 | CYHS2401689 | | 药品批准文号 | 国药准字 H20263426 | | 药品批准文号有效期 | 至 2031 年 02 月 24 日 | | 上市许可持有人 | 名称：浙江昂利康制药股份有限公司 地址：浙江省嵊州市嵊州大道北 号 1000 | | 生产企业 | 名称：浙江昂利康制药股份有限公司 地址：绍兴嵊州市嵊州大道北 号 1000 | | 审批结论 | 根据 ...

Group 1 - Beixin Road and Bridge won a bid for a project worth 751 million yuan [1] - Beijing Keri won bids for projects totaling approximately 588 million yuan [2] - Saifu Tian's subsidiary Anhui Meidalen resumed production after maintenance [3] Group 2 - ST Songfa's subsidiary signed contracts for the construction of three ultra-large oil tankers, with a total contract value of approximately 300 to 400 million USD [4] - Kanghong Pharmaceutical received clinical trial approval for KHN707 tablets for insomnia [5] - Koweil reported a 32.32% year-on-year increase in net profit for 2025 [6] Group 3 - Shandong Haohua plans to invest 4.837 billion yuan in a soda ash facility upgrade for energy efficiency and environmental protection [7] - Changsha Bank's president Zhang Man applied for resignation due to job changes [8] - Wens Foodstuff Group plans to repurchase A-shares worth between 800 million and 1.2 billion yuan [9] Group 4 - SMIC's application for issuing shares to purchase assets was accepted by the Shanghai Stock Exchange [10] - Sainuo Medical reported a 14.53% year-on-year increase in revenue for 2025 [11] - Chaohongji opened a new direct store in January [12] Group 5 - Taoli Bread's controlling shareholder plans to reduce holdings by up to 3% [13] - Anglikang's subsidiary received approval for a veterinary drug product [14] - Tuori New Energy's controlling shareholder plans to reduce holdings by up to 3% [15] Group 6 - Qianyuan Pharmaceutical acquired 20% equity in Qianyuan Hailisheng for 77.36 million yuan [16] - Zhaobiao Co. shareholders plan to reduce holdings by up to 3% [17] - Sichuan Gold shareholders plan to reduce holdings by up to 2.119% [18] Group 7 - Longhua New Materials shareholders plan to reduce holdings by up to 1.63% [19][20] - Yutong Technology plans to acquire 60% of Gelbert for approximately 654.37 million euros [21] - ST Xinhua Jin was investigated for information disclosure violations [22] Group 8 - Sanjing Guojian's new drug application for an anti-IL-4Rα monoclonal antibody was accepted [23] - Tianshan Aluminum's controlling shareholders plan to reduce holdings by up to 2% [24] - Baisheng Intelligent's vice chairman plans to reduce holdings by up to 3% [25] Group 9 - Huaxin Environmental Protection's directors and executives plan to reduce holdings by up to 1.4% [26] - Zhongjin Irradiation shareholders plan to reduce holdings by up to 1% [27] - Gree Electric's major shareholder plans to reduce holdings by up to 2% [28] Group 10 - Yuekang Pharmaceutical's controlling shareholder's shares will be auctioned [29] - Hengxuan Technology reported a 27.75% year-on-year increase in net profit for 2025 [30] - Dae Oriental plans to invest 50 million yuan in the Junfu Zhi Cun Fund [31] Group 11 - Tailin Micro's application for issuing shares and raising matching funds was accepted by the Shanghai Stock Exchange [32] - ST Yanshi warned of potential delisting risks due to stock price volatility and financial issues [33] - Bertley plans to acquire a controlling stake in Yubei Turning [34] Group 12 - Whirlpool's subsidiary plans to invest 30 million USD in purchasing shares of Whirlpool Group [35] - Frantac's controlling shareholder is planning a share transfer, leading to a temporary suspension of stock trading [36]

Group 1 - Company received the drug supplement application approval notice for Domperidone tablets from the National Medical Products Administration, which is equivalent to passing the consistency evaluation and will enhance market competitiveness [1][2] - Domperidone tablets are indicated for dyspepsia, abdominal distension, belching, nausea, vomiting, and abdominal pain [1][5] Group 2 - The subsidiary, Zhejiang Anglikang Animal Health Technology Co., Ltd., obtained the approval number for "Inhalation Sevoflurane (for pets)" from the Ministry of Agriculture and Rural Affairs, indicating compliance with production and sales conditions [4][6] - The approval of the veterinary drug will enrich the company's product portfolio and positively impact the strategic layout for pet medications [6]

Core Viewpoint - The company announced that its subsidiary, Zhejiang Anglikang Animal Health Technology Co., Ltd., has received approval from the Ministry of Agriculture and Rural Affairs for a veterinary drug product, "Inhalation Sevoflurane (for pets)," which is now ready for market sales [2]. Group 1 - The approved veterinary drug has the product approval number 111187016 and comes in a specification of 120ml [2]. - The product is intended for use in pet surgical anesthesia induction and maintenance [2]. - The approval is valid until February 8, 2031, indicating a long-term market presence [2].

Group 1 - The core point of the article is that Anglikon has received a notification from the National Medical Products Administration regarding the approval of the supplementary application for Domperidone tablets [2] Group 2 - The announcement was made on February 25, indicating a significant regulatory milestone for the company [2] - The approval is expected to enhance the company's product portfolio and market presence in the pharmaceutical industry [2]

一、药品基本信息 二、药品的其他相关信息 多潘立酮片用于消化不良、腹胀、嗳气、恶心、呕吐、腹部胀痛。 三、对公司的影响 1 证券代码：002940 证券简称：昂利康 公告编号：2026-004 浙江昂利康制药股份有限公司 关于获得药品补充申请批准通知书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 近日，浙江昂利康制药股份有限公司（以下简称"公司"）收到国家药品监 督管理局（以下简称"国家药监局"）签发的多潘立酮片《药品补充申请批准通 知书》。现将有关情况公告如下： | 药品通用名称 | 多潘立酮片 | | --- | --- | | 剂型 | 片剂 | | 申请内容 | 仿制药质量和疗效一致性评价，同时申请以下变更：1、处方 | | | 变更；2、生产工艺变更；3、批量变更；4、注册标准变更 | | 规格 | 10mg | | 受理号 | CYHB2550104 | | 原药品批准文号 | 国药准字 H20093779 | | 上市许可持有人 | 名称：浙江昂利康制药股份有限公司 | | | 地址：浙江省嵊州市嵊州大道北 1000 号 | | 生产企 ...

证券代码：002940 证券简称：昂利康 公告编号：2026-005 浙江昂利康制药股份有限公司 关于子公司获得兽药产品批准文号批件的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 近日，浙江昂利康制药股份有限公司（以下简称"公司"）子公司浙江昂利 康动保科技有限公司（以下简称"动保科技"）收到中华人民共和国农业农村部 核准签发的"吸入用七氟烷（宠物用）"兽药产品批准文号批件。现将有关情况 公告如下： 浙江昂利康制药股份有限公司 二、产品基本情况 吸入用七氟烷（宠物用）用于外科手术的麻醉诱导和麻醉维持。 三、对公司的影响 公司已按照《兽药管理条例》《兽药产品批准文号管理办法》等规定的要求 取得吸入用七氟烷（宠物用）兽药产品批准文号批件，该兽药具备生产上市销售 条件。 该兽药批准文号的取得可进一步丰富公司产品品类，对推动宠物用药战略布 局、促进公司发展具有积极意义。 因兽药产品的上市销售容易受到国家政策、市场环境变化等因素影响，具体 销售情况存在较大不确定性。敬请广大投资者审慎决策，注意投资风险。 1 特此公告。 一、批件基本信息 | 通用名称 | 吸入用 ...

Core Viewpoint - The company Anglikon (002940.SZ) announced that its subsidiary, Zhejiang Anglikon Animal Health Technology Co., Ltd., received approval from the Ministry of Agriculture and Rural Affairs of the People's Republic of China for the veterinary drug product "Inhalation Sevoflurane (for pets)" [1] Group 1 - The approved product is intended for use in anesthesia induction and maintenance during surgical procedures for pets [1]

Group 1 - The core point of the article is that Anglikon (002940.SZ) has received approval from the National Medical Products Administration for the drug Domperidone tablets, which has passed the consistency evaluation of quality and efficacy for generic drugs [2] - The drug is indicated for conditions such as dyspepsia, abdominal distension, belching, nausea, vomiting, and abdominal pain [2] - Passing the consistency evaluation is expected to enhance the company's market competitiveness, although sales may be influenced by policy and market environment factors, leading to uncertainty [2]